Sangamo Therapeutics (SGMOQ) Non-Current Deffered Revenue (2012 - 2025)

Sangamo Therapeutics has reported Non-Current Deffered Revenue for 14 years, with the latest figure at $5.9 million in Q4 2025.

• On a quarterly basis, Non-Current Deffered Revenue changed 0.0% year-over-year to $5.9 million in Q4 2025; TTM through Dec 2025 was $5.9 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $5.9 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue was $5.9 million for Q4 2025 at Sangamo Therapeutics, roughly flat from $5.9 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $222.3 million in Q1 2021, with the low at $1.8 million in Q1 2023.
• Average Non-Current Deffered Revenue over 5 years is $93.6 million, with a median of $112.5 million recorded in 2022.
• The sharpest annual moves came in 2021 and 2023: Non-Current Deffered Revenue soared 195.29% in 2021, then plunged 98.79% in 2023.
• Over 5 years, Non-Current Deffered Revenue stood at $166.8 million in 2021, then slumped by 34.42% to $109.4 million in 2022, then slumped by 98.34% to $1.8 million in 2023, then soared by 223.46% to $5.9 million in 2024, then changed by 0.0% to $5.9 million in 2025.
• The last three Non-Current Deffered Revenue figures came in at $5.9 million (Q4 2025), $5.9 million (Q3 2025), and $5.9 million (Q2 2025), per Business Quant data.